Prevention of diseases caused by Staphylococcus aureus using the peptide RIP

Naomi Balaban, L. Vincent Collins, James S Cullor, Emma B. Hume, Enrique Medina-Acosta, Olney Vieira da Motta, Richard O'Callaghan, Paul V. Rossitto, Mark E. Shirtliff, Leonardo Serafim da Silveira, Andrej Tarkowski, Jose V Torres

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)1301-1311
Number of pages11
JournalPeptides
Volume21
Issue number9
DOIs
StatePublished - 2000

Fingerprint

Pathology
Staphylococcus aureus
Peptides
Infectious Arthritis
Cellulitis
Keratitis
Mastitis
Osteomyelitis
Rabbits
Infection

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Balaban, N., Collins, L. V., Cullor, J. S., Hume, E. B., Medina-Acosta, E., Vieira da Motta, O., ... Torres, J. V. (2000). Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides, 21(9), 1301-1311. https://doi.org/10.1016/S0196-9781(00)00272-2

Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. / Balaban, Naomi; Collins, L. Vincent; Cullor, James S; Hume, Emma B.; Medina-Acosta, Enrique; Vieira da Motta, Olney; O'Callaghan, Richard; Rossitto, Paul V.; Shirtliff, Mark E.; Serafim da Silveira, Leonardo; Tarkowski, Andrej; Torres, Jose V.

In: Peptides, Vol. 21, No. 9, 2000, p. 1301-1311.

Research output: Contribution to journalArticle

Balaban, N, Collins, LV, Cullor, JS, Hume, EB, Medina-Acosta, E, Vieira da Motta, O, O'Callaghan, R, Rossitto, PV, Shirtliff, ME, Serafim da Silveira, L, Tarkowski, A & Torres, JV 2000, 'Prevention of diseases caused by Staphylococcus aureus using the peptide RIP', Peptides, vol. 21, no. 9, pp. 1301-1311. https://doi.org/10.1016/S0196-9781(00)00272-2
Balaban N, Collins LV, Cullor JS, Hume EB, Medina-Acosta E, Vieira da Motta O et al. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides. 2000;21(9):1301-1311. https://doi.org/10.1016/S0196-9781(00)00272-2
Balaban, Naomi ; Collins, L. Vincent ; Cullor, James S ; Hume, Emma B. ; Medina-Acosta, Enrique ; Vieira da Motta, Olney ; O'Callaghan, Richard ; Rossitto, Paul V. ; Shirtliff, Mark E. ; Serafim da Silveira, Leonardo ; Tarkowski, Andrej ; Torres, Jose V. / Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. In: Peptides. 2000 ; Vol. 21, No. 9. pp. 1301-1311.
@article{5e8621589cce4f9c8b54373c0bd7d617,
title = "Prevention of diseases caused by Staphylococcus aureus using the peptide RIP",
abstract = "Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.",
author = "Naomi Balaban and Collins, {L. Vincent} and Cullor, {James S} and Hume, {Emma B.} and Enrique Medina-Acosta and {Vieira da Motta}, Olney and Richard O'Callaghan and Rossitto, {Paul V.} and Shirtliff, {Mark E.} and {Serafim da Silveira}, Leonardo and Andrej Tarkowski and Torres, {Jose V}",
year = "2000",
doi = "10.1016/S0196-9781(00)00272-2",
language = "English (US)",
volume = "21",
pages = "1301--1311",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Prevention of diseases caused by Staphylococcus aureus using the peptide RIP

AU - Balaban, Naomi

AU - Collins, L. Vincent

AU - Cullor, James S

AU - Hume, Emma B.

AU - Medina-Acosta, Enrique

AU - Vieira da Motta, Olney

AU - O'Callaghan, Richard

AU - Rossitto, Paul V.

AU - Shirtliff, Mark E.

AU - Serafim da Silveira, Leonardo

AU - Tarkowski, Andrej

AU - Torres, Jose V

PY - 2000

Y1 - 2000

N2 - Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.

AB - Staphylococcus aureus causes many diseases including cellulitis, keratitis, osteomyelitis, septic arthritis and mastitis. The heptapeptide RIP has been shown to prevent cellulitis in mice, which was induced by S. aureus strain Smith diffuse. Here we show that RIP can also significantly reduce the overall pathology and delay the onset of disease symptoms in several other models of S. aureus infections, including: keratitis (tested in rabbits against S. aureus 8325-4), osteomyelitis (tested in rabbits against S. aureus MS), mastitis (tested in cows against S. aureus Newbould 305, AE-1, and environmental infections) and septic arthritis (tested in mice against S. aureus LS-1). These findings substantiate that RIP is not strain specific in its inhibitory activity and that RIP is an effective inhibitor of bacterial pathology at multiple body sites following diverse routes and doses of administration. These findings strongly evidence the potential value of RIP as a chemotherapeutic agent. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033783672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033783672&partnerID=8YFLogxK

U2 - 10.1016/S0196-9781(00)00272-2

DO - 10.1016/S0196-9781(00)00272-2

M3 - Article

C2 - 11072116

AN - SCOPUS:0033783672

VL - 21

SP - 1301

EP - 1311

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 9

ER -